{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:54:43Z","timestamp":1787766883322,"version":"build-2784847793"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-03042-4","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:34:23Z","timestamp":1767072863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis on randomized-controlled trials"],"prefix":"10.1186","volume":"15","author":[{"given":"Yucong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaquan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8444-4518","authenticated-orcid":false,"given":"Hanlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2003-3339","authenticated-orcid":false,"given":"Wen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"10","key":"3042_CR1","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","volume":"7","author":"WHO CVD Risk Chart Working Group","year":"2019","unstructured":"WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332\u201345.","journal-title":"Lancet Glob Health"},{"key":"3042_CR2","doi-asserted-by":"crossref","unstructured":"The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41(2):105\u201314.","DOI":"10.1016\/0895-4356(88)90084-4"},{"issue":"4","key":"3042_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","volume":"16","author":"D Zhao","year":"2019","unstructured":"Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203\u201312.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"3042_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pop.2017.11.003","volume":"45","author":"BV Reamy","year":"2018","unstructured":"Reamy BV, Williams PM, Kuckel DP. Prevention of cardiovascular disease. Prim Care. 2018;45(1):25\u201344.","journal-title":"Prim Care"},{"issue":"1","key":"3042_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archinte.166.1.71","volume":"166","author":"LH Kuller","year":"2006","unstructured":"Kuller LH, Arnold AM, Psaty BM, Robbins JA, O\u2019Leary DH, Tracy RP, et al. 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med. 2006;166(1):71\u20138.","journal-title":"Arch Intern Med"},{"key":"3042_CR6","doi-asserted-by":"crossref","unstructured":"Chaves PHM, Kuller LH, O\u2019Leary DH, Manolio TA, Newman AB, Cardiovascular Health Study. Subclinical cardiovascular disease in older adults: insights from the Cardiovascular Health Study. Am J Geriatr Cardiol. 2004;13(3):137\u201351.","DOI":"10.1111\/j.1076-7460.2004.02120.x"},{"issue":"19","key":"3042_CR7","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1001\/archinte.163.19.2315","volume":"163","author":"AB Newman","year":"2003","unstructured":"Newman AB, Arnold AM, Naydeck BL, Fried LP, Burke GL, Enright P, et al. \u201cSuccessful aging\u201d: effect of subclinical cardiovascular disease. Arch Intern Med. 2003;163(19):2315\u201322.","journal-title":"Arch Intern Med"},{"key":"3042_CR8","doi-asserted-by":"crossref","unstructured":"O\u2019Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340(1):14\u201322.","DOI":"10.1056\/NEJM199901073400103"},{"issue":"1","key":"3042_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12933-023-02052-7","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Arshi B, Waqas K, Lu T, Bos D, Ikram MA, et al. Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study. Cardiovasc Diabetol. 2023;22(1):326.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"3042_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.amjhyper.2006.04.002","volume":"19","author":"BM Psaty","year":"2006","unstructured":"Psaty BM, Arnold AM, Olson J, Saad MF, Shea S, Post W, et al. Association between levels of blood pressure and measures of subclinical disease multi-ethnic study of atherosclerosis. Am J Hypertens. 2006;19(11):1110\u20137.","journal-title":"Am J Hypertens"},{"issue":"32","key":"3042_CR11","doi-asserted-by":"publisher","first-page":"e29609","DOI":"10.1097\/MD.0000000000029609","volume":"101","author":"HJ Ko","year":"2022","unstructured":"Ko HJ, Liu CC, Hsu PJ, Hu KC, Hung CL, Yu LY, et al. Risk assessment indicators and brachial-ankle pulse wave velocity to predict atherosclerotic cardiovascular disease. Medicine (Baltimore). 2022;101(32):e29609.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"3042_CR12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/JOM.0b013e3181f4385c","volume":"52","author":"PN Joseph","year":"2010","unstructured":"Joseph PN, Violanti JM, Donahue R, Andrew ME, Trevisan M, Burchfiel CM, et al. Endothelial function, a biomarker of subclinical cardiovascular disease, in urban police officers. J Occup Environ Med. 2010;52(10):1004\u20138.","journal-title":"J Occup Environ Med"},{"issue":"4 Pt 1","key":"3042_CR13","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1161\/01.CIR.88.4.1444","volume":"88","author":"RB Devereux","year":"1993","unstructured":"Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88(4 Pt 1):1444\u201355.","journal-title":"Circulation"},{"key":"3042_CR14","doi-asserted-by":"crossref","unstructured":"N T, Te F, N D, Dj W. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. British journal of pharmacology. 2020;177(24). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31721165\/. Cited 2024 Jan 11.","DOI":"10.1111\/bph.14920"},{"issue":"1","key":"3042_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.eururo.2013.08.048","volume":"65","author":"AM Isidori","year":"2014","unstructured":"Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65(1):99\u2013112.","journal-title":"Eur Urol"},{"issue":"2","key":"3042_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/stem.789","volume":"30","author":"NN Hoke","year":"2012","unstructured":"Hoke NN, Salloum FN, Kass DA, Das A, Kukreja RC. Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells. 2012;30(2):326\u201335.","journal-title":"Stem Cells"},{"issue":"2","key":"3042_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yjmcc.2003.11.001","volume":"36","author":"RC Kukreja","year":"2004","unstructured":"Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, et al. Cardioprotection with phosphodiesterase-5 inhibition\u2013a novel preconditioning strategy. J Mol Cell Cardiol. 2004;36(2):165\u201373.","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"3042_CR18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1161\/ATVBAHA.109.201327","volume":"30","author":"M Sahara","year":"2010","unstructured":"Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1\/vascular endothelial growth factor pathway. Arterioscler Thromb Vasc Biol. 2010;30(7):1315\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3042_CR19","unstructured":"McMurray JG, Feldman RA, Auerbach SM, Deriesthal H, Wilson N, Multicenter Study Group. Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag. 2007;3(6):975\u201381."},{"key":"3042_CR20","doi-asserted-by":"crossref","unstructured":"Christiansen E, Guirguis WR, Cox D, Osterloh IH, Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res. 2000;12(3):177\u201382.","DOI":"10.1038\/sj.ijir.3900527"},{"issue":"39","key":"3042_CR21","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.2174\/138161281939131127110156","volume":"19","author":"RC Kukreja","year":"2013","unstructured":"Kukreja RC. Sildenafil and cardioprotection. Curr Pharm Des. 2013;19(39):6842\u20137.","journal-title":"Curr Pharm Des"},{"key":"3042_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","volume":"147","author":"A Das","year":"2015","unstructured":"Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12\u201321.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3042_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.hipert.2022.08.001","volume":"40","author":"SF Mohamed","year":"2023","unstructured":"Mohamed SF, Khayeka-Wandabwa C, Muthuri S, Ngomi NN, Kyobutungi C, Haregu TN. Carotid intima media thickness (CIMT) in adults in the AWI-Gen Nairobi site study: profiles and predictors. Hipertens Riesgo Vasc. 2023;40(1):5\u201315.","journal-title":"Hipertens Riesgo Vasc"},{"issue":"1","key":"3042_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11906-019-1006-z","volume":"22","author":"A Vall\u00e9e","year":"2020","unstructured":"Vall\u00e9e A, Cinaud A, Protogerou A, Zhang Y, Topouchian J, Safar ME, et al. Arterial Stiffness and Coronary Ischemia: New Aspects and Paradigms. Curr Hypertens Rep. 2020;22(1):5.","journal-title":"Curr Hypertens Rep"},{"issue":"30","key":"3042_CR25","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/eurheartj\/ehz350","volume":"40","author":"DHJ Thijssen","year":"2019","unstructured":"Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019;40(30):2534\u201347.","journal-title":"Eur Heart J"},{"issue":"9","key":"3042_CR26","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1161\/01.ATV.0000237750.44469.88","volume":"26","author":"GP Fadini","year":"2006","unstructured":"Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol. 2006;26(9):2140\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"372","key":"3042_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71.","journal-title":"BMJ"},{"issue":"1","key":"3042_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s40001-023-01158-8","volume":"28","author":"R Chai","year":"2023","unstructured":"Chai R, Ye Z, Wu Q, Xue W, Shi S, Du Y, et al. Circadian rhythm in cardiovascular diseases: a bibliometric analysis of the past, present, and future. Eur J Med Res. 2023;28(1):194.","journal-title":"Eur J Med Res"},{"issue":"343","key":"3042_CR29","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.","journal-title":"BMJ"},{"issue":"9","key":"3042_CR30","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1177\/0962280219889080","volume":"29","author":"S McGrath","year":"2020","unstructured":"McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A, DEPRESsion Screening Data (DEPRESSD) Collaboration. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020;29(9):2520\u201337.","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"3042_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"3","key":"3042_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cardfail.2007.11.006","volume":"14","author":"A Behling","year":"2008","unstructured":"Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5\u2019-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail. 2008;14(3):189\u201397.","journal-title":"J Card Fail"},{"issue":"6","key":"3042_CR33","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/01.CIR.0000155252.23933.2D","volume":"111","author":"T Gori","year":"2005","unstructured":"Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005;111(6):742\u20136.","journal-title":"Circulation"},{"issue":"7","key":"3042_CR34","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/S0735-1097(02)02139-3","volume":"40","author":"JPJ Halcox","year":"2002","unstructured":"Halcox JPJ, Nour KRA, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40(7):1232\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3042_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.amjcard.2005.06.091","volume":"15;96","author":"K Hirata","year":"2005","unstructured":"Hirata K, Adji A, Vlachopoulos C, O\u2019Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol. 2005;15;96(10):1436\u201340.","journal-title":"Am J Cardiol"},{"issue":"4","key":"3042_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1042\/CS20040266","volume":"108","author":"K Hryniewicz","year":"2005","unstructured":"Hryniewicz K, Dimayuga C, Hudaihed A, Androne AS, Zheng H, Jankowski K, et al. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci Lond. 2005;108(4):331\u20138.","journal-title":"Clin Sci Lond"},{"issue":"3","key":"3042_CR37","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0735-1097(00)00790-7","volume":"36","author":"SD Katz","year":"2000","unstructured":"Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36(3):845\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3042_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0895-7061(03)01006-9","volume":"16","author":"RS Schofield","year":"2003","unstructured":"Schofield RS, Edwards DG, Schuler BT, Estrada J, Aranda JM, Pauly DF, et al. Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens. 2003;16(10):874\u20137.","journal-title":"Am J Hypertens"},{"issue":"4","key":"3042_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1191\/1358863x03vm509ra","volume":"8","author":"C Vlachopoulos","year":"2003","unstructured":"Vlachopoulos C, Hirata K, O\u2019Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med. 2003;8(4):243\u20138.","journal-title":"Vasc Med"},{"issue":"3","key":"3042_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ajh\/hps057","volume":"26","author":"TM Attin\u00e0","year":"2013","unstructured":"Attin\u00e0 TM, Drummond ID, Malatino LS, Maxwell SR, Webb DJ. Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. Am J Hypertens. 2013;26(3):342\u201350.","journal-title":"Am J Hypertens"},{"issue":"1","key":"3042_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2006.09.035","volume":"196","author":"M Bocchio","year":"2008","unstructured":"Bocchio M, Pelliccione F, Passaquale G, Mihalca R, Necozione S, Desideri G, et al. Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. Atherosclerosis. 2008;196(1):313\u20139.","journal-title":"Atherosclerosis"},{"key":"3042_CR42","doi-asserted-by":"crossref","unstructured":"Diomedi M, Sallustio F, Rizzato B, Ferrante F, Leone G, Spera E, et al. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study. Neurology. 2005;65(6):919\u201321.","DOI":"10.1212\/01.wnl.0000173835.12308.bb"},{"key":"3042_CR43","doi-asserted-by":"crossref","unstructured":"Dishy V, Sofowora G, Harris PA, Kandcer M, Zhan F, Wood AJ, et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther. 2001;70(3):270\u20139.","DOI":"10.1067\/mcp.2001.117995"},{"issue":"2","key":"3042_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2125.2003.01974.x","volume":"57","author":"V Dishy","year":"2004","unstructured":"Dishy V, Harris PA, Pierce R, Prasad HC, Sofowora G, Bonar HL, et al. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol. 2004;57(2):209\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"3042_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1161\/CIRCULATIONAHA.119.044352","volume":"141","author":"DJ Goldberg","year":"2020","unstructured":"Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, et al. Results of the FUEL Trial. Circulation. 2020;141(8):641\u201351.","journal-title":"Circulation"},{"issue":"12","key":"3042_CR46","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1016\/j.jacc.2004.09.041","volume":"44","author":"M Guazzi","year":"2004","unstructured":"Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44(12):2339\u201348.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3042_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.clpt.2004.06.003","volume":"76","author":"M Guazzi","year":"2004","unstructured":"Guazzi M, Tumminello G, Di Marco F, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther. 2004;76(4):371\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"3042_CR48","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","volume":"50","author":"M Guazzi","year":"2007","unstructured":"Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50(22):2136\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3042_CR49","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.clpt.6100306","volume":"83","author":"M Guazzi","year":"2008","unstructured":"Guazzi M, Casali M, Berti F, Rossoni G, Colonna VD, Guazzi MD. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther. 2008;83(2):336\u201341.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3042_CR50","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.urology.2011.02.070","volume":"78","author":"V Javaroni","year":"2011","unstructured":"Javaroni V, Queiroz-Miguez M, Abreu-Casanova M, Oigman W, Neves MF. Brachial flow-mediated dilation correlates with vardenafil response in hypertensive men with vasculogenic erectile dysfunction. Urology. 2011;78(2):368\u201374.","journal-title":"Urology"},{"issue":"4","key":"3042_CR51","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.urology.2012.06.042","volume":"80","author":"V Javaroni","year":"2012","unstructured":"Javaroni V, Queiroz Miguez M, Burla A, Oigman W, Neves MF. Response to on-demand vardenafil was improved by its daily usage in hypertensive men. Urology. 2012;80(4):858\u201364.","journal-title":"Urology"},{"issue":"5","key":"3042_CR52","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/01.HYP.0000068202.42431.CC","volume":"41","author":"M Kimura","year":"2003","unstructured":"Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K, et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension. 2003;41(5):1106\u201310.","journal-title":"Hypertension"},{"issue":"6","key":"3042_CR53","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2174\/1570161120666220827154417","volume":"20","author":"M Larios-C\u00e1rdenas","year":"2022","unstructured":"Larios-C\u00e1rdenas M, Gonz\u00e1lez-Radillo OI, Trujillo-Quir\u00f3s J, Cardona-M\u00fcller D, Barocio-Pantoja M, Cardona-Mu\u00f1oz EG, et al. Tadalafil improves haemodynamics and arterial stiffness but not flow- mediated dilation in grade 1 obesity. A single-dose, placebo-controlled clinical trial. Curr Vasc Pharmacol. 2022;20(6):527\u201333.","journal-title":"Curr Vasc Pharmacol"},{"issue":"10","key":"3042_CR54","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.jhh.1001244","volume":"15","author":"A Mahmud","year":"2001","unstructured":"Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens. 2001;15(10):707\u201313.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"3042_CR55","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/FJC.0000000000000168","volume":"65","author":"D Morisawa","year":"2015","unstructured":"Morisawa D, Hirotani S, Sugahara M, Fukui M, Ando T, Naito Y, et al. Hemodynamic response to sildenafil in patients with decompensated congestive heart failure can be predicted by deceleration time of transmitral flow. J Cardiovasc Pharmacol. 2015;65(1):72\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"3042_CR56","doi-asserted-by":"publisher","first-page":"H1486","DOI":"10.1152\/ajpheart.00301.2018","volume":"315","author":"P Rodriguez-Miguelez","year":"2018","unstructured":"Rodriguez-Miguelez P, Lee N, Tucker MA, Cs\u00e1nyi G, McKie KT, Forseen C, et al. Sildenafil improves vascular endothelial function in patients with cystic fibrosis. Am J Physiol Heart Circ Physiol. 2018;315(5):H1486\u201394.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"3042_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00246-015-1238-x","volume":"37","author":"MR Sabri","year":"2016","unstructured":"Sabri MR, Zolfi-Gol A, Ahmadi A, Haghjooy-Javanmard S. Effect of tadalafil on myocardial and endothelial function and exercise performance after modified Fontan operation. Pediatr Cardiol. 2016;37(1):55\u201361.","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"3042_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00228-013-1611-8","volume":"70","author":"RC Santos","year":"2014","unstructured":"Santos RC, de Faria APC, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, et al. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014;70(2):147\u201354.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"3042_CR59","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/and.12153","volume":"46","author":"A Simsek","year":"2014","unstructured":"Simsek A, Ozbek E, Oncu M. Effect of tadalafil and 3-hydroxy-3-methylglutaryl coenzyme A inhibitor statin on the haemodynamics of cavernous and brachial arteries. Andrologia. 2014;46(7):808\u201313.","journal-title":"Andrologia"},{"issue":"4","key":"3042_CR60","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1097\/01.ju.0000057051.76422.11","volume":"169","author":"I Stanopoulos","year":"2003","unstructured":"Stanopoulos I, Hatzichristou D, Tryfon S, Tzortzis V, Apostolidis A, Argyropoulou P. Effects of sildenafil on cardiopulmonary responses during stress. J Urol. 2003;169(4):1417\u201321.","journal-title":"J Urol"},{"issue":"11","key":"3042_CR61","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/S0735-1097(02)02563-9","volume":"40","author":"U Thadani","year":"2002","unstructured":"Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002;40(11):2006\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3042_CR62","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1016\/j.juro.2009.08.025","volume":"182","author":"Y Vardi","year":"2009","unstructured":"Vardi Y, Appel B, Ofer Y, Greunwald I, Dayan L, Jacob G. Effect of chronic sildenafil treatment on penile endothelial function: a randomized, double-blind, placebo controlled study. J Urol. 2009;182(6):2850\u20135.","journal-title":"J Urol"},{"issue":"11 Pt 1","key":"3042_CR63","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.amjhyper.2004.06.027","volume":"17","author":"C Vlachopoulos","year":"2004","unstructured":"Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K, Stefanadis C. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens. 2004;17(11 Pt 1):1040\u20134.","journal-title":"Am J Hypertens"},{"issue":"8","key":"3042_CR64","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/0091270011413586","volume":"52","author":"C Vlachopoulos","year":"2012","unstructured":"Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Samentzas A, Aggelis A, et al. Beneficial effect of vardenafil on aortic stiffness and wave reflections. J Clin Pharmacol. 2012;52(8):1215\u201321.","journal-title":"J Clin Pharmacol"},{"key":"3042_CR65","doi-asserted-by":"crossref","unstructured":"La Vignera S, Condorelli RA, Vicari E, D\u2019Agata R, Calogero AE. Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation. Int J Impot Res. 2011;23(5):200\u20135.","DOI":"10.1038\/ijir.2011.28"},{"issue":"2","key":"3042_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41443-018-0103-x","volume":"31","author":"ES Pelit","year":"2019","unstructured":"Pelit ES, Dokumac\u0131 D\u015e, Kati B, Ya\u011fmur \u0130, Arslan E, Tun\u00e7tekin A, et al. Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors. Int J Impot Res. 2019;31(2):139\u201344.","journal-title":"Int J Impot Res"},{"issue":"4","key":"3042_CR67","first-page":"177","volume":"14","author":"MR Sabri","year":"2018","unstructured":"Sabri MR, Shoja M, Shoja M, Hosseinzadeh M. The effect of tadalafil on functional capacity and echocardiographic parameters in patients with repaired Tetralogy of Fallot. ARYA Atherosclerosis. 2018;14(4):177\u201382.","journal-title":"ARYA Atherosclerosis"},{"issue":"6","key":"3042_CR68","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2164\/jandrol.111.015289","volume":"33","author":"H Porst","year":"2012","unstructured":"Porst H, Brock GB, Kula K, Moncada I, Montorsi F, Basson BR, et al. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl. 2012;33(6):1305\u201322.","journal-title":"J Androl"},{"issue":"2","key":"3042_CR69","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/sj.ijir.3901513","volume":"19","author":"A Aversa","year":"2007","unstructured":"Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19(2):200\u20137.","journal-title":"Int J Impot Res"},{"issue":"1","key":"3042_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1464-5491.2007.02298.x","volume":"25","author":"A Aversa","year":"2008","unstructured":"Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, et al. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med. 2008;25(1):37\u201344.","journal-title":"Diabet Med"},{"issue":"5","key":"3042_CR71","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.ijir.3901465","volume":"18","author":"C Foresta","year":"2006","unstructured":"Foresta C, Ferlin A, De Toni L, Lana A, Vinanzi C, Galan A, et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res. 2006;18(5):484\u20138.","journal-title":"Int J Impot Res"},{"issue":"5","key":"3042_CR72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.ijir.3901454","volume":"18","author":"E Mazo","year":"2006","unstructured":"Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res. 2006;18(5):464\u20139.","journal-title":"Int J Impot Res"},{"key":"3042_CR73","doi-asserted-by":"crossref","unstructured":"McLaughlin K, Lytvyn Y, Luca MC, Liuni A, Gori T, Parker JD. Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: a human in vivo study. Am J Physiol Heart Circ Physiol. 2014;307(6):H888\u2013894.","DOI":"10.1152\/ajpheart.00215.2014"},{"issue":"1","key":"3042_CR74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.esxm.2018.11.008","volume":"7","author":"S Pattanaik","year":"2019","unstructured":"Pattanaik S, Kaundal P, Mavuduru RS, Singh SK, Mandal AK. Endothelial dysfunction in patients with erectile dysfunction: a double-blind, randomized-control trial using tadalafil. Sex Med. 2019;7(1):41\u20137.","journal-title":"Sex Med"},{"issue":"12","key":"3042_CR75","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00228-013-1571-z","volume":"69","author":"T Quinaglia","year":"2013","unstructured":"Quinaglia T, de Faria APC, Fontana V, Barbaro NR, Sabbatini AR, Sert\u00f3rio JT, et al. Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension. Eur J Clin Pharmacol. 2013;69(12):2027\u201336.","journal-title":"Eur J Clin Pharmacol"},{"key":"3042_CR76","doi-asserted-by":"crossref","unstructured":"Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005;47(2):214\u201320. discussion 220\u2013222.","DOI":"10.1016\/j.eururo.2004.10.002"},{"issue":"12","key":"3042_CR77","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","volume":"49","author":"PD Shenoy","year":"2010","unstructured":"Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49(12):2420\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3042_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00345-005-0021-7","volume":"23","author":"F Sommer","year":"2005","unstructured":"Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol. 2005;23(6):385\u201392.","journal-title":"World J Urol"},{"issue":"2","key":"3042_CR79","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/dmrr.921","volume":"25","author":"A Stirban","year":"2009","unstructured":"Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ, et al. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev. 2009;25(2):136\u201343.","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"3042_CR80","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2337\/diacare.25.8.1336","volume":"25","author":"C Desouza","year":"2002","unstructured":"Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002;25(8):1336\u20139.","journal-title":"Diabetes Care"},{"key":"3042_CR81","doi-asserted-by":"crossref","unstructured":"Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Vinanzi C, et al. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur Urol. 2007;51(5):1411\u20137. discussion 1417\u20131419.","DOI":"10.1016\/j.eururo.2006.08.052"},{"issue":"2","key":"3042_CR82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2164\/jandrol.111.013342","volume":"33","author":"S La Vignera","year":"2012","unstructured":"La Vignera S, Condorelli R, Vicari E, D\u2019Agata R, Calogero AE. Endothelial antioxidant compound prolonged the endothelial antiapoptotic effects registered after tadalafil treatment in patients with arterial erectile dysfunction. J Androl. 2012;33(2):170\u20135.","journal-title":"J Androl"},{"issue":"11","key":"3042_CR83","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/1471-0528.17163","volume":"129","author":"JM Turner","year":"2022","unstructured":"Turner JM, Russo F, Deprest J, Mol BW, Kumar S. Phosphodiesterase-5 inhibitors in pregnancy: systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. BJOG. 2022;129(11):1817\u201331.","journal-title":"BJOG"},{"key":"3042_CR84","doi-asserted-by":"crossref","unstructured":"Soulaidopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP, Vlachopoulos C. Long-term Effects of Phosphodiesterase-5 Inhibitors on Cardiovascular Outcomes and Death: A Systematic Review and Meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024;10(5):403-12.","DOI":"10.1093\/ehjcvp\/pvae029"},{"issue":"24","key":"3042_CR85","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1111\/bph.14920","volume":"177","author":"N Tzoumas","year":"2020","unstructured":"Tzoumas N, Farrah TE, Dhaun N, Webb DJ. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. Br J Pharmacol. 2020;177(24):5467\u201388.","journal-title":"Br J Pharmacol"},{"issue":"15","key":"3042_CR86","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","volume":"104","author":"DC Hutchings","year":"2018","unstructured":"Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018;104(15):1244\u201350.","journal-title":"Heart"},{"key":"3042_CR87","doi-asserted-by":"publisher","first-page":"106563","DOI":"10.1016\/j.vph.2019.05.003","volume":"118\u2013119","author":"L Omarjee","year":"2019","unstructured":"Omarjee L, Le Pabic E, Custaud MA, Fontaine C, Locher C, Renault A, et al. Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study. Vascul Pharmacol. 2019;118\u2013119:106563.","journal-title":"Vascul Pharmacol"},{"issue":"2","key":"3042_CR88","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/jnc.13454","volume":"136","author":"V G\u00f3mez-Vallejo","year":"2016","unstructured":"G\u00f3mez-Vallejo V, Ugarte A, Garc\u00eda-Barroso C, Cuadrado-Tejedor M, Szczupak B, Dopeso-Reyes IG, et al. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. J Neurochem. 2016;136(2):403\u201315.","journal-title":"J Neurochem"},{"issue":"4","key":"3042_CR89","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5527\/wjn.v3.i4.220","volume":"3","author":"E Suzuki","year":"2014","unstructured":"Suzuki E, Nishimatsu H, Oba S, Takahashi M, Homma Y. Chronic kidney disease and erectile dysfunction. World J Nephrol. 2014;3(4):220\u20139.","journal-title":"World J Nephrol"},{"issue":"11","key":"3042_CR90","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1681\/ASN.2015050473","volume":"27","author":"W Scheele","year":"2016","unstructured":"Scheele W, Diamond S, Gale J, Clerin V, Tamimi N, Le V, et al. Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy. J Am Soc Nephrol. 2016;27(11):3459\u201368.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"3042_CR91","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","volume":"102","author":"SG Anderson","year":"2016","unstructured":"Anderson SG, Hutchings DC, Woodward M, Rahimi K, Rutter MK, Kirby M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750\u20136.","journal-title":"Heart"},{"key":"3042_CR92","doi-asserted-by":"publisher","first-page":"1174984","DOI":"10.3389\/fcell.2023.1174984","volume":"11","author":"XH Shi","year":"2023","unstructured":"Shi XH, Dong L, Zhang RH, Zhou DJ, Ling SG, Shao L, et al. Relationships between quantitative retinal microvascular characteristics and cognitive function based on automated artificial intelligence measurements. Front Cell Dev Biol. 2023;11:1174984.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"3042_CR93","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","volume":"64","author":"BR Lindman","year":"2014","unstructured":"Lindman BR, D\u00e1vila-Rom\u00e1n VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol. 2014;64(6):541\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3042_CR94","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.pcd.2022.09.004","volume":"16","author":"S Seidu","year":"2022","unstructured":"Seidu S, Cebri\u00e1n A, Kunutsor SK, Khunti K. Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: a systematic review and meta-analysis. Prim Care Diabetes. 2022;16(5):601\u201313.","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"3042_CR95","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12872-017-0576-4","volume":"17","author":"IC Hwang","year":"2017","unstructured":"Hwang IC, Kim YJ, Park JB, Yoon YE, Lee SP, Kim HK, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17(1):150.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"3042_CR96","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1161\/CIRCULATIONAHA.120.046361","volume":"142","author":"P Willeit","year":"2020","unstructured":"Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, et al. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation. 2020;142(7):621\u201342.","journal-title":"Circulation"},{"issue":"16","key":"3042_CR97","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jacc.2012.06.034","volume":"60","author":"D Baldassarre","year":"2012","unstructured":"Baldassarre D, Hamsten A, Veglia F, de Faire U, Humphries SE, Smit AJ, et al. Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. J Am Coll Cardiol. 2012;60(16):1489\u201399.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3042_CR98","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10554-010-9616-1","volume":"26","author":"Y Inaba","year":"2010","unstructured":"Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging. 2010;26(6):631\u201340.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"9","key":"3042_CR99","doi-asserted-by":"publisher","first-page":"e1003282","DOI":"10.1371\/journal.pmed.1003282","volume":"17","author":"EM Yubero-Serrano","year":"2020","unstructured":"Yubero-Serrano EM, Fernandez-Gandara C, Garcia-Rios A, Rangel-Zu\u00f1iga OA, Gutierrez-Mariscal FM, Torres-Pe\u00f1a JD, et al. Mediterranean diet and endothelial function in patients with coronary heart disease: an analysis of the CORDIOPREV randomized controlled trial. PLoS Med. 2020;17(9):e1003282.","journal-title":"PLoS Med"},{"issue":"9","key":"3042_CR100","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1161\/CIRCULATIONAHA.123.067620","volume":"150","author":"S Rajagopalan","year":"2024","unstructured":"Rajagopalan S, Dobre M, Dazard JE, Vergara-Martel A, Connelly K, Farkouh ME, et al. Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Circulation. 2024;150(9):663\u201376.","journal-title":"Circulation"},{"issue":"2","key":"3042_CR101","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1152\/ajpregu.00121.2021","volume":"321","author":"EJ Pekas","year":"2021","unstructured":"Pekas EJ, Wooden TK, Yadav SK, Park SY. Body mass-normalized moderate dose of dietary nitrate intake improves endothelial function and walking capacity in patients with peripheral artery disease. Am J Physiol Regul Integr Comp Physiol. 2021;321(2):R162\u201373.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"7","key":"3042_CR102","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1136\/jim-2021-002237","volume":"70","author":"J Zhang","year":"2022","unstructured":"Zhang J, Xian TZ, Wu MX, Li C, Wang W, Man F, et al. Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial. J Investig Med. 2022;70(7):1529\u201335.","journal-title":"J Investig Med"},{"issue":"1","key":"3042_CR103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12902-022-01007-5","volume":"22","author":"X Lin","year":"2022","unstructured":"Lin X, Chen Y, Lu W, Li J, Fu L, Yin J, et al. Ultrasonography evaluation on the protective effect of combination therapy of beraprost sodium and aspirin on arteries occlusion and stiffness in patients with type 2 diabetes mellitus - a prospective, randomized study. BMC Endocr Disord. 2022;22(1):87.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"3042_CR104","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.ajkd.2014.02.022","volume":"64","author":"S Headley","year":"2014","unstructured":"Headley S, Germain M, Wood R, Joubert J, Milch C, Evans E, et al. Short-term aerobic exercise and vascular function in CKD stage 3: a randomized controlled trial. Am J Kidney Dis. 2014;64(2):222\u20139.","journal-title":"Am J Kidney Dis"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-03042-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-03042-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:03:20Z","timestamp":1769789000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-025-03042-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-03042-4","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"9 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this study, all methods were performed in accordance with the relevant guidelines and regulations. Ethical approval, consent to participate, and written informed consent were not necessary since our study was a meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}